Sports Medicine Market Analysis by Applications, End-Users, Top Companies, Future Growth Opportunities, Product Type, Global Forecast To 2020

The MarketWatch News Department was not involved in the creation of this content.

Japan, Japan, Wed, 02 Dec 2020 14:20:31 / Comserve Inc. / — Over the years, the sports medicine market has witnessed various technological advancements made to ensure and provide better recovery and rehabilitative measures for injuries caused during sports or physical activities.

The sports medicine market comprises products and devices used by professional or non-professional athletes or sportspersons to prevent and protect themselves from injuries as well as devices that enhance performance. The sports medicine products play an important role in the rehabilitation, recovery, protection, endurance, and monitoring of athletes while playing sports. Over the years, the sports medicine market has witnessed various technological advancements made to ensure and provide better recovery and rehabilitative measures for injuries caused during sports or physical activities.

These advancements have led to the development of new products and therapies to treat sports injuries. Various market players are focusing on the introduction of newer products and treatment options for sports injuries. A number of key players are competing to secure larger shares of the market by launching new products. Arthrex, Inc. (U.S.), Smith & Nephew PLC (U.K.), DePuy Synthes Companies (U.S.), Stryker Corporation (U.S.), and CONMED Corporation (U.S.) are the top five players of this market

Request to Fill The Form To get Sample Copy of This Report: https://www.sdki.jp/sample-request-61031

“The Final Report will cover the impact analysis of COVID-19 on this industry (Global And Regional Market).”

In 2015, the body reconstruction & repair products segment is expected to account for the largest share of the global sports medicine market, by product, while the knee injuries segment is expected to account for the largest share of the sports medicine market, by application.

In 2015, North America is expected to account for the largest share of the global sports medicine market, followed by Europe, Asia-Pacific, and the Rest of the World (RoW). In the coming years, the sports medicine market is expected to witness the highest growth rate in the Asia-Pacific region, with emphasis on India, China, and Japan. The entry of international players, increasing government initiatives, and rising awareness regarding sports medicine in emerging nations like India and China are expected to drive the market in these regions.

The sports medicine market witnesses high competitive intensity as there are several big and many small firms with similar product offerings. These companies adopt various growth strategies (agreements, partnerships, joint ventures, geographic expansions, new product launches, and acquisitions) to increase their market shares and establish a strong foothold in the global market.

“The Final Report will cover the impact analysis of COVID-19 on this industry (Global And Regional Market).”

Reasons to Buy the Report:

The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn helps firms garner a greater market share. Firms purchasing the report could use any one or a combination of the below-mentioned five strategies (market penetration, product development/innovation, market

Read more

Global Personalized Medicine Scientific & Commercial Aspects Market Report 2020-2029 with Profiles of 298 Companies Along with 583 Collaborations

Dublin, Oct. 30, 2020 (GLOBE NEWSWIRE) — The “Personalized Medicine – Scientific & Commercial Aspects” report from Jain PharmaBiotech has been added to ResearchAndMarkets.com’s offering.

The concept of personalized medicine described in this report remains remains the best way to integrate new technologies such as nanobiotechnology for improving healthcare.

Increase in efficacy and safety of treatment by individualizing it has benefits in financial terms. Information is presented to show that personalized medicine will be cost-effective in healthcare systems. For the pharmaceutical companies, segmentation of the market may not leave room for conventional blockbusters but smaller and exclusive markets for personalized medicines would be profitable. Marketing opportunities for such a system are described with market estimates from 2019-2029.

Profiles of 298 companies involved in developing technologies for personalized medicines, along with 583 collaborations are included.
The aim of personalized medicine or individualized treatment is to match the right drug to the right patient and, in some cases, even to design the appropriate treatment for a patient according to his/her genotype. This report describes the latest concepts of development of personalized medicine based on pharmacogenomics, pharmacogenetics,pharmacoproteomics, and metabolomics.

Basic technologies of molecular diagnostics play an important role, particularly those for single nucleotide polymorphism (SNP) genotyping. Biomarkers play an important role in personalized medicine. Diagnosis is integrated with therapy for selection of treatment as well for monitoring the results. There is emphasis on early detection and prevention of disease in modern medicine. Biochip/microarray technologies and next generation sequencing are also important.

Pharmacogenetics, the study of influence of genetic factors on drug action and metabolism, is used for predicting adverse reactions of drugs. Several enzymes are involved in drug metabolism of which the most important ones are those belonging to the family of cytochrome P450. The knowledge of the effects of polymorphisms of genes for the enzymes is applied in drug discovery and development as well as in clinical use of drugs. Cost-effective methods for genotyping are being developed and it would be desirable to include this information in the patient’s record for the guidance of the physician to individualize the treatment.

Pharmacogenomics, a term that overlaps with pharmacogenetics but is distinct, deals with the application of genomics to drug discovery and development. It involves the mechanism of action of drugs on cells as revealed by gene expression patterns. Pharmacoproteomics is an important contribution to personalized medicine as it is a more functional representation of patient-to-patient variation than that provided by genotyping.A ‘pharmacometabonomic’ approach to personalizing drug treatment is also described.

Biological therapies such as those which use patient’s own cells are considered to be personalized medicines. Vaccines are prepared from individual patient’s tumor cells. Individualized therapeutic strategies using monoclonal bodies can be directed at specific genetic and immunologic targets. Ex vivo gene therapy involves the genetic modification of the patient’s cells in vitro, prior to reimplantation of these cells in the patient’s body.

Various technologies are integrated to develop personalized therapies for specific therapeutic areas described in the report. Examples of

Read more

Albertsons Companies thanks generous customers for record-breaking donations toward Nourishing Neighbors childhood hunger relief

Customers donated $9.3 million at checkstands in September to enable 37.5 million healthy breakfasts; company and customer donations have now topped $110 million in 2020

BOISE, Idaho, Oct. 29, 2020 (GLOBE NEWSWIRE) — Thanks to the generosity of customers, the Albertsons Companies Nourishing Neighbors community relief fund raised a record $9.3 million in its September campaign to provide healthy breakfasts for children in need across its market areas. The funds – raised at the register and directed to local organizations in each store’s community – will enable 37.5 million breakfasts throughout the country.

Nourishing Neighbors is a charitable program of the Albertsons Companies Foundation, which is working to eradicate hunger in America.

“We are so humbled by the generosity of our customers,” said Christy Duncan Anderson, Executive Director of Albertsons Companies Foundation. “When we partner with our communities through Nourishing Neighbors to tackle issues that affect the most vulnerable among us, we help ensure every child in our neighborhoods can get a healthy start to their day.”

The donations were made at checkstands at Albertsons, Safeway, Vons, Jewel-Osco, Shaw’s, Star Market, Tom Thumb, Randalls, ACME, and other Albertsons Cos. stores. Each store has partnered with a local charity that will use the donations to fund healthy breakfasts for children in their community.

Today, 14 million children in America do not know where their next meal will come from. In total, the resources provided to Nourishing Neighbors grant recipient organizations can enable all of the following:

  • Enough milk and juice to fill an Olympic-sized swimming pool

  • 460,000 pounds of fruit and vegetables — roughly three times the weight of the Space Shuttle

  • Over 18 tons of peanut butter — roughly the same weight as a semi-tractor trailer

  • Enough oatmeal and cereal to fill 25 cars

  • Enough granola bars to give one to every resident in the state of Pennsylvania

$110 million raised for hunger relief in 2020

Since the onset of the pandemic in early 2020 created unprecedented uncertainty and need throughout the country, Nourishing Neighbors has raised $57 million at the register from generous customers for community hunger relief. Albertsons Cos. provided a $53 million commitment to the fund, bringing the total to $110 million to date this year.

Albertsons Cos. has a long-standing commitment to hunger relief. In the last five years, the company has donated more than $2 billion in food to food banks and other hunger relief agencies, expanding their standing as one of the biggest retail supporters of hunger relief in the country. These donations were in addition to hundreds of tons of food contributed through local and regional food drives.

For more information about Albertsons Cos.’ commitment to hunger relief, please visit here.

About Albertsons Companies
Locally great and nationally strong, Albertsons Companies is a leading food and drug retailer in the United States. The company operates stores across 34 states and the District of Columbia under 20 well-known banners including Albertsons, Safeway, Vons, Jewel-Osco, Shaw’s, Acme, Tom Thumb, Randalls, United Supermarkets,

Read more

Health Insurance Companies Working the System

Health Insurance Companies Working the System

PR Newswire

HUNTINGTON BEACH, Calif., Oct. 24, 2020

HUNTINGTON BEACH, Calif., Oct. 24, 2020 /PRNewswire/ — Many Californians are familiar with health insurance companies like Anthem Blue Cross, Blue Shield, Healthnet, Cigna or Aetna. We pay them a premium each month and expect that when we have a claim, they would do their part and cover us by paying our physicians and medical facilities. Although these are large companies, with many subscribers, COAST Surgery Center discovers that when they pay out their claims, they pay peanuts. How do they get away with that? Coast Surgery Center reveals their inside secret.

Coast Surgery Center (PRNewsfoto/Coast Surgery Center)
Coast Surgery Center (PRNewsfoto/Coast Surgery Center)

Since California law allows health insurers 40 days to accept or deny a claim, then allows them to notify patients every additional 30 days if they need more time, this allows for a loophole with no real deadline. So these insurers create a special department, which some call PPR (Pre-payment Plan Review), to intentionally delay payments by sending out general denial letters.  These letters provide auto-generated reasons like “incorrectly billed, missing signatures, missing documentation, or missing medical records,” in order to buy them time. They would give patients, doctors, and facilities the run-around and give excuses that may not even be relevant to the claim.

These large insurance companies pay lobbyists to help create laws that allow them loopholes to be able to get away with cheating their customers. Customers then purchase insurance policies that don’t even cover them when they need it. When customers get frustrated and demand the insurance to pay or want to ring the alarm, the insurance company then pays, but pays Medicare rate, instead of paying the Usual Customary Reasonable (UCR) or (RC) rates as they really should be. So medical providers and facilities get nearly nothing. This doesn’t make any sense when insurance premiums increase annually, and coverage keep decreasing.

California tax payers including patients, doctors, and facilities fund the Department of Insurance and the Department of Managed Healthcare (DMHC) so that they can ensure consumers of their healthcare rights and to protect consumers from being cheated. Yet these departments have either turned a blind eye towards these insurance companies or are not aware of their tactics. These Departments should be protecting consumers and investigate these insurance payout processes because they are working the system and using the loophole to scam customers of millions of dollars in premiums and paying out next to nothing or not at all. So instead of protecting the health insurance companies and letting them work the system, the Dept of Insurance and DMHC should be protecting patients.

If you are a patient, doctor or facility that have received notices from your insurance company or from a Pre-payment Plan Review department and have been struggling to get your claims paid, call COAST Surgery Center at 855-263-9968 and share with us your struggles.

Cision
Cision

View original content to download multimedia:http://www.prnewswire.com/news-releases/health-insurance-companies-working-the-system-301159122.html

SOURCE Coast Surgery Center

Source

Read more

Global Tumor Infiltrating Lymphocytes TIL Immunotherapy Markers Market Size Research Companies Clinical Trials Outlook Report 2025

Tumor Infiltrating Lymphocytes Therapy To Transform The Global Immunotherapy Market Over next Decade Says Kuick Research

DELHI, India, Oct. 22, 2020 (GLOBE NEWSWIRE) — “Global Tumor Infiltrating Lymphocytes Immunotherapy Market Opportunity & Clinical Trials Insight 2025” Report Highlights:

  • Tumor Infiltrating Lymphocytes Immunotherapy Pipeline: 3 Therapies

  • Highest Phase of Development for Tumor Infiltrating Lymphocytes Immunotherapy : Phase II Trials

  • USA To Dominate Global Tumor Infiltrating Lymphocytes Immunotherapy Market Landscape

  • Expected Cost For Tumor Infiltrating Lymphocytes Immunotherapy: > US$ 200,000

  • TIL Therapy Can Drive Personalized Cancer Therapy Market

Download Report:

https://www.kuickresearch.com/report-global-tumor-tnfiltrating-lymphocytes-immunotherapy-therapy-til-market-size-sales-clinical-trials-lifileucel-ln144-ln145-tilt123

The tumor-infiltrating lymphocyte therapy market is a potent immunotherapy available for the cancer patients but the survival of the therapy in a market where there are plenty of other immunotherapies was not easy. The therapy in a short period of time has made its way through from all the challenges and led to a stage where the availability of the therapy is highly appreciated and praised. The therapy when compared with the other available therapies such as immune checkpoint therapy and monoclonal antibodies is delivering some of the applications that are not observed for other therapies. An important application or advantage of the therapy over the other therapies is the inclination of the tumor-infiltrating lymphocyte therapy market towards personalized therapy. In today’s generation, arrival of personalized therapy is highly appreciated as it has led to an overall survival rate that is more than ever in the past few decades. Also, the therapy has provided the patients with the treatment that is highly required.

All the recent developments that have been characterized have made the therapy produce durable response against the different types of cancer that are prevalent in the patients. Tumor-infiltrating lymphocyte therapy market, above all the therapies that are available is estimated to produce stronger immune response as the technical approach that is coupled with the therapy at laboratory levels are tremendous and fascinating. Being novel and innovative have also led to the arrival of the therapy as a top and pioneering frontier for the pharmaceutical industry.

In the overall development and expansion of the market at a level that is higher than most of the dominating markets of the world, many major research centers and advanced organizations such as National Institute of Health are demonstrating research activity work that is unmatchable with any other ongoing work for other therapies. The market has also achieved a high status when referred to the number of publications that it has done in the past few years. The number of published papers that carry different applications of the therapy has increased multiple times in the past few years. This however indicates the interest of the researchers and the physicians in making the therapy full time available for the cancer patients.

Research work such as the use of TILs in various different cancer types also demonstrated that the combination of autologous TIL and cyclophosphamide could induce regression of metastases and many others have helped the market to establish a landmark in the

Read more

Mira Mesa dentist gets six years for false claims to insurance companies

SAN DIEGO (CNS) – A former Mira Mesa dentist who bilked insurance companies out of hundreds of thousands of dollars by submitting claims for procedures she never performed, including hundreds of supposed root canals, has been sentenced to six years in state prison, the San Diego County District Attorney’s Office announced today.

April Rose Ambrosio, 59, pleaded guilty to three counts of insurance fraud earlier this year for fraudulently billing insurance companies for $866,700, for which she received more than $400,000 from 10 insurance companies, according to prosecutors.

The DA’s Office said Ambrosio falsely claimed she performed 800 root canals on 100 patients, despite not having specialized training as an endodontist to perform such procedures.

Ambrosio was sentenced earlier this month, and in addition to a six- year prison term, was ordered to pay $405,633 in restitution. Her license to practice dentistry was also suspended last year, a few months after she was charged.

Prosecutors say the fraud occurred between 2014 and 2018. During that time, Ambrosio billed for work she said occurred on days her office was closed and billed for more than 100 root canals during a three- month period, all of which were supposedly performed for a family of four, according to the DA’s Office. She also billed for root canals on teeth patients didn’t have or double billed for teeth she previously said she performed root canals on, the DA’s Office said.

“The way this defendant bilked the system is astounding,” District Attorney Summer Stephan said. “Unfortunately, when insurance companies get ripped off, consumers ultimately pay the price through higher premiums.”

appId : '412634405581169',

xfbml : true, version : 'v2.9' }); }; (function(d, s, id){ var js, fjs = d.getElementsByTagName(s)[0]; if (d.getElementById(id)) {return;} js = d.createElement(s); js.id = id; js.src = "https://connect.facebook.net/en_US/sdk.js"; fjs.parentNode.insertBefore(js, fjs); }(document, 'script', 'facebook-jssdk'));

Source Article

Read more